Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of JNJ-64417184 in Healthy Volunteers
NCT04121052Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-64417184 in respiratory syncytial virus infection (RSV) (16 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Plasma Concentration of JNJ-64417184 at 120 hours. Started Oct 2019; status: completed.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04121052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121052.